Lundbeck held its Annual General Meeting on 26 March 2014 at the company's registered office

        Print
| Source: H. Lundbeck A/S
multilang-release

Valby, Copenhagen, 2014-03-26 16:41 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 26 March 2014 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting on 26 March 2014 the proposal to prepare the annual report and hereby also the quarterly reports of the company in English only was approved.

The report by the Board of Directors was adopted and the annual report was approved.

The General Meeting approved the remuneration for the Board of Directors for 2014.

The General Meeting approved the dividend of DKK 2.77 per share of DKK 5 nominal value proposed by the Board of Directors.

Håkan Björklund, Christian Dyvig, Thorleif Krarup, Melanie G. Lee and Lars Rasmussen were re-elected, while Terrie Curran was elected to the Board of Directors.  Jes Østergaard did not stand for re-election. Immediately after the general meeting, the Board of Directors elected Håkan Björklund as Chairman and Christian Dyvig as Deputy Chairman of the Board of Directors.

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Thorleif Krarup, Håkan Björklund and Lars Rasmussen were elected as members of the Audit Committee. Håkan Björklund, Lars Rasmussen and Terrie Curran were elected as members of the Remuneration Committee. Melanie G. Lee and Christian Dyvig were elected as members of the Scientific Committee.

The Board of Directors of H. Lundbeck A/S will hereafter comprise:

  • Håkan Björklund (Chairman)
  • Christian Dyvig (Deputy Chairman)
  • Thorleif Krarup
  • Melanie G. Lee
  • Lars Rasmussen
  • Terrie Curran
  • Mona Elisabeth Elster (employee representative)
  • Jørn Møller Mayntzhusen (employee representative)
  • Henrik Sindal Jensen (employee representative)

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal of the Board of Directors to amend the company's "Remuneration guidelines for the Board of Directors and the Executive Management of H. Lundbeck A/S" was approved.

The proposal of the Board of Directors to insert an authorisation in the Articles of Association to increase the share capital by a nominal amount of up to DKK 40.000.000 with or without pre-emption rights for the existing shareholders and the proposal to give the Board of Directors authorisation to let the company acquire own shares were adopted. 

 

The proposals from a shareholder to include additional financial information in the notice convening the general meeting, to simplify online access to financial reports and accounting figures and on provision of meals at general meetings were withdrawn and the proposals were instead put forward as recommendations to the Board of Directors . 

No other business was handled at the Annual General Meeting.

The Board of Directors

Lundbeck contacts

Investors: Media:
   
Palle Holm Olesen Mads Kronborg
Chief Specialist, Investor Relations Media Relations Manager
palo@lundbeck.com mavk@lundbeck.com
+45 36 43 24 26 +45 36 43 30 00
   
Jens Høyer  
Specialist, Investor Relations  
jshr@lundbeck.com  
+45 36 43 33 86  
   

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s disease, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and stroke.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3 billion in 2013 (EUR 2.0 billion; USD 2.7 billion).